Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
In 2012, genomics tiptoed into the doctor’s office, gene therapy rose again, and man and machine united.
The technique could help patients with currently untreatable diseases such as Huntington’s.
A biotech company founded by Craig Mello, codiscoverer of RNAi, brings its first self-delivering interfering RNA to clinical trial.
New methods for delivering the therapies to the target tissue could boost a wavering field.
In first human trial, particles successfully reach cancer cells and silence the target gene.
Gene-silencing techniques for bacteria could mean better treatments for infections and more-efficient biofuel production.
Novel delivery agents could mean a more targeted way to turn off disease genes.
Nanotubes can transport RNA into the human immune system’s white blood cells, making the cells less vulnerable to attack by the HIV virus.